SCHEDULE 13G/A: Suvretta Capital Management and Affiliates Disclose Significant 9.9% Stake in 89bio, Inc.

Suvretta Capital Management, LLC, along with Averill Master Fund, Ltd. and Aaron Cowen, has filed an amended Schedule 13G disclosing a combined beneficial ownership of 9.9% in 89bio, Inc.'s common stock as of March 31, 2025.

Summary

• Suvretta Capital Management, LLC, Averill Master Fund, Ltd., and Aaron Cowen collectively reported beneficial ownership in 89bio, Inc. common stock.
• As of March 31, 2025, Suvretta Capital Management, LLC and Aaron Cowen each beneficially owned 14,611,409 shares, representing 9.9% of the class.
• Averill Master Fund, Ltd. beneficially owned 12,918,677 shares, representing 8.8% of the class.
• The reported shares include those directly held by Averill Master Fund, Ltd., an advisory client of Suvretta Capital Management, LLC, and shares that may be acquired upon the exercise of pre-funded warrants.
• These pre-funded warrants have an exercise price of $0.001 per share and no expiration date, but their exercise is limited such that beneficial ownership does not exceed 9.99% of outstanding common stock, though this limit can be increased to 19.99% with 61 days' notice.
• Aaron Cowen is identified as the control person for Suvretta Capital Management, LLC.

Sentiment

Score: 5

Explanation: The document is a factual disclosure of beneficial ownership, which is neutral in sentiment. It does not contain positive or negative operational news about the company.

Risks

• The exercise of pre-funded warrants is subject to a beneficial ownership limitation, typically 9.99% of outstanding common stock, which means not all warrants are presently exercisable.
• This limitation can be increased to 19.99% by written notice to the Issuer, but such an increase would not be effective until 61 days after the notice is delivered.

Future Outlook

NA

Industry Context

This Schedule 13G filing is a routine disclosure of significant beneficial ownership by an institutional investor and its affiliates in a publicly traded biotechnology company. Such filings provide transparency regarding large shareholder positions, which can influence market perception and corporate governance dynamics within the biotech sector.

Related Party Transactions

• Averill Master Fund, Ltd. is an advisory client of Suvretta Capital Management, LLC, and its holdings are deemed indirectly beneficially owned by Suvretta and Aaron Cowen.
• Aaron Cowen is the control person for Suvretta Capital Management, LLC, establishing a control relationship among the reporting entities.

Stakeholder Impact

• Shareholders: Provides transparency regarding significant institutional ownership, which can influence market sentiment and potentially corporate governance discussions.
• Company Management: Awareness of a large, active shareholder group may influence strategic decisions or engagement.

Key Dates

Keywords

89bio Inc., Suvretta Capital Management, Averill Master Fund, Aaron Cowen, Schedule 13G, Beneficial Ownership, Common Stock, Pre-Funded Warrants, Investment Management, SEC Filing